| CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma |
| GP Canellos |
|
JCO May 1 1997: 1713–1716.
[PDF]
|
 |
| Bleomycin in germ cell tumor therapy: not all regimens are created equal |
| DF Bajorin and GJ Bosl |
|
JCO May 1 1997: 1717–1719.
[PDF]
|
|
|
Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma |
| |
AM Stoppa, R Bouabdallah, C Chabannon, G Novakovitch, N Vey, J Camerlo, D Blaise, L Xerri, M Resbeut, D Di Stefano, VJ Bardou, JA Gastaut, and D Maraninchi |
| |
JCO May 1 1997: 1722–1729.
[Abstract]
[PDF]
|
|
|
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas |
| |
RA Stahel, LM Jost, H Honegger, E Betts, ME Goebel, and A Nagler |
| |
JCO May 1 1997: 1730–1735.
[Abstract]
[PDF]
|
|
|
Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation |
| |
SJ Horning, RT Hoppe, J Mason, BW Brown, SL Hancock, D Baer, and SA Rosenberg |
| |
JCO May 1 1997: 1736–1744.
[Abstract]
[PDF]
|
|
|
Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B |
| |
AY Lee, JM Connors, P Klimo, SE O'Reilly, and RD Gascoyne |
| |
JCO May 1 1997: 1745–1753.
[Abstract]
[PDF]
|
|
|
Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma |
| |
C Altehoefer, U Blum, J Bathmann, C Wustenberg, P Uhrmeister, J Laubenberger, W Lange, J Schwarzkopf, E Moser, and M Langer |
| |
JCO May 1 1997: 1754–1760.
[Abstract]
[PDF]
|
|
|
Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors |
| |
AC Pavlick, H Gerdes, and CS Portlock |
| |
JCO May 1 1997: 1761–1766.
[Abstract]
[PDF]
|
|
|
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings |
| |
R Szydlo, JM Goldman, JP Klein, RP Gale, RC Ash, FH Bach, BA Bradley, JT Casper, N Flomenberg, JL Gajewski, E Gluckman, PJ Henslee-Downey, JM Hows, N Jacobsen, HJ Kolb, B Lowenberg, T Masaoka, PA Rowlings, PM Sondel, DW van Bekkum, JJ van Rood, MR Vowels, MJ Zhang, and MM Horowitz |
| |
JCO May 1 1997: 1767–1777.
[Abstract]
[PDF]
|
|
|
Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T- cell leukemia |
| |
Y Yamada, Y Hatta, K Murata, K Sugawara, S Ikeda, M Mine, T Maeda, Y Hirakata, S Kamihira, K Tsukasaki, S Ogawa, H Hirai, HP Koeffler, and M Tomonaga |
| |
JCO May 1 1997: 1778–1785.
[Abstract]
[PDF]
|
|
|
Secondary cytogenetic changes in acute promyelocytic leukemia-- prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study |
| |
JL Slack, DC Arthur, D Lawrence, K Mrozek, RJ Mayer, FR Davey, R Tantravahi, MJ Pettenati, S Bigner, AJ Carroll, KW Rao, CA Schiffer, and CD Bloomfield |
| |
JCO May 1 1997: 1786–1795.
[Abstract]
[PDF]
|
|
|
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia |
| |
SM Kornblau, E Estey, T Madden, HT Tran, S Zhao, U Consoli, V Snell, G Sanchez- Williams, H Kantarjian, M Keating, RA Newman, and M Andreeff |
| |
JCO May 1 1997: 1796–1802.
[Abstract]
[PDF]
|
|
|
Second cancer risk in hairy cell leukemia: analysis of 350 patients |
| |
R Kurzrock, SS Strom, E Estey, S O'Brien, MJ Keating, H Jiang, T Adams, and M Talpaz |
| |
JCO May 1 1997: 1803–1810.
[Abstract]
[PDF]
|
|
|
Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma |
| |
DW Shaw, JR Geyer, MS Berger, J Milstein, and KL Lindsley |
| |
JCO May 1 1997: 1811–1813.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors |
| |
ML Graham, JE Herndon, 2nd, JR Casey, S Chaffee, GH Ciocci, JP Krischer, J Kurtzberg, MJ Laughlin, DC Longee, JF Olson, N Paleologus, CN Pennington, and HS Friedman |
| |
JCO May 1 1997: 1814–1823.
[Abstract]
[PDF]
|
|
|
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group |
| |
A Thyss, S Suciu, Y Bertrand, F Mazingue, A Robert, E Vilmer, F Mechinaud, Y Benoit, P Brock, A Ferster, P Lutz, P Boutard, G Marguerite, E Plouvier, G Michel, D Plantaz, M Munzer, X Rialland, JM Chantraine, L Norton, G Solbu, N Philippe, and J Otten |
| |
JCO May 1 1997: 1824–1830.
[Abstract]
[PDF]
|
|
|
Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma |
| |
KM Kelly, RB Womer, PH Sorensen, QB Xiong, and FG Barr |
| |
JCO May 1 1997: 1831–1836.
[Abstract]
[PDF]
|
|
|
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group |
| |
R de Wit, G Stoter, SB Kaye, DT Sleijfer, WG Jones, WW ten Bokkel Huinink, LA Rea, L Collette, and R Sylvester |
| |
JCO May 1 1997: 1837–1843.
[Abstract]
[PDF]
|
|
|
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial |
| |
A Horwich, DT Sleijfer, SD Fossa, SB Kaye, RT Oliver, MH Cullen, GM Mead, R de Wit, PH de Mulder, DP Dearnaley, PA Cook, RJ Sylvester, and SP Stenning |
| |
JCO May 1 1997: 1844–1852.
[Abstract]
[PDF]
|
|
|
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma |
| |
JA McCaffrey, S Hilton, M Mazumdar, S Sadan, WK Kelly, HI Scher, and DF Bajorin |
| |
JCO May 1 1997: 1853–1857.
[Abstract]
[PDF]
|
|
|
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 |
| |
B Fisher, S Anderson, DL Wickerham, A DeCillis, N Dimitrov, E Mamounas, N Wolmark, R Pugh, JN Atkins, FJ Meyers, N Abramson, J Wolter, RS Bornstein, L Levy, EH Romond, V Caggiano, M Grimaldi, P Jochimsen, and P Deckers |
| |
JCO May 1 1997: 1858–1869.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America |
| |
KH Antman, PA Rowlings, WP Vaughan, CJ Pelz, JW Fay, KK Fields, CO Freytes, RP Gale, BE Hillner, HK Holland, MJ Kennedy, JP Klein, HM Lazarus, PL McCarthy, Jr, R Saez, G Spitzer, EA Stadtmauer, SF Williams, S Wolff, KA Sobocinski, JO Armitage, and MM Horowitz |
| |
JCO May 1 1997: 1870–1879.
[Abstract]
[PDF]
|
|
|
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study |
| |
JA Sparano, D Neuberg, JH Glick, NJ Robert, LJ Goldstein, GW Sledge, and W Wood |
| |
JCO May 1 1997: 1880–1884.
[Abstract]
[PDF]
|
|
|
Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism |
| |
D Busse, FW Busch, F Bohnenstengel, M Eichelbaum, P Fischer, J Opalinska, K Schumacher, E Schweizer, and HK Kroemer |
| |
JCO May 1 1997: 1885–1896.
[Abstract]
[PDF]
|
|
|
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin |
| |
DJ Stewart, WK Evans, FA Shepherd, KS Wilson, KI Pritchard, ME Trudeau, JJ Wilson, and K Martz |
| |
JCO May 1 1997: 1897–1905.
[Abstract]
[PDF]
|
|
|
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer |
| |
L Gianni, L Vigano, A Locatelli, G Capri, A Giani, E Tarenzi, and G Bonadonna |
| |
JCO May 1 1997: 1906–1915.
[Abstract]
[PDF]
|
|
|
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study |
| |
RM Elledge, S Green, L Howes, GM Clark, M Berardo, DC Allred, R Pugh, D Ciocca, P Ravdin, J O'Sullivan, S Rivkin, S Martino, and CK Osborne |
| |
JCO May 1 1997: 1916–1922.
[Abstract]
[PDF]
|
|
|
Prognostic importance of thymidylate synthase expression in early breast cancer |
| |
BC Pestalozzi, HF Peterson, RD Gelber, A Goldhirsch, BA Gusterson, H Trihia, J Lindtner, H Cortes-Funes, E Simmoncini, MJ Byrne, R Golouh, CM Rudenstam, M Castiglione-Gertsch, CJ Allegra, and PG Johnston |
| |
JCO May 1 1997: 1923–1931.
[Abstract]
[PDF]
|
|
|
Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions |
| |
CC Pao, CJ Tseng, CY Lin, FP Yang, JJ Hor, DS Yao, and S Hsueh |
| |
JCO May 1 1997: 1932–1937.
[Abstract]
[PDF]
|
|
|
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer |
| |
G Bolis, G Favalli, S Danese, F Zanaboni, G Mangili, C Scarabelli, S Tateo, MG Valsecchi, G Scarfone, G Richiardi, L Frigerio, M Melpignano, A Villa, and F Parazzini |
| |
JCO May 1 1997: 1938–1944.
[Abstract]
[PDF]
|
|
|
Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients |
| |
SK Chambers, JT Chambers, CA Davis, EI Kohorn, PE Schwartz, MI Lorber, RE Handschumacher, and G Pizzorno |
| |
JCO May 1 1997: 1945–1952.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer |
| |
MT Huizing, LJ van Warmerdam, H Rosing, MC Schaefers, A Lai, TJ Helmerhorst, CH Veenhof, MJ Birkhofer, S Rodenhuis, JH Beijnen, and WW ten Bokkel Huinink |
| |
JCO May 1 1997: 1953–1964.
[Abstract]
[PDF]
|
|
|
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose- limiting |
| |
AN Gordon, CA Stringer, CM Matthews, DL Willis, and J Nemunaitis |
| |
JCO May 1 1997: 1965–1973.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors |
| |
S O'Reilly, LB Grochow, RC Donehower, TL Chen, K Bowling, NR Hartman, RF Struck, and EK Rowinsky |
| |
JCO May 1 1997: 1974–1984.
[Abstract]
[PDF]
|
|
|
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations |
| |
EC Kohn, WD Figg, GA Sarosy, KS Bauer, PA Davis, MJ Soltis, A Thompkins, LA Liotta, and E Reed |
| |
JCO May 1 1997: 1985–1993.
[Abstract]
[PDF]
|
|
|
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer |
| |
BJ Giantonio, RK Alpaugh, J Schultz, C McAleer, DW Newton, B Shannon, Y Guedez, M Kotb, L Vitek, R Persson, PO Gunnarsson, T Kalland, M Dohlsten, B Persson, and LM Weiner |
| |
JCO May 1 1997: 1994–2007.
[Abstract]
[PDF]
|
|
|
Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis |
| |
A Costa, R Doci, C Mochen, P Bignami, A Faranda, L Gennari, and R Silvestrini |
| |
JCO May 1 1997: 2008–2014.
[Abstract]
[PDF]
|
|
|
Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis |
| |
Y Kajiyama, M Tsurumaru, H Udagawa, K Tsutsumi, Y Kinoshita, M Ueno, and H Akiyama |
| |
JCO May 1 1997: 2015–2021.
[Abstract]
[PDF]
|
|
|
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients |
| |
S Earlam, C Glover, M Davies, C Fordy, and TG Allen-Mersh |
| |
JCO May 1 1997: 2022–2029.
[Abstract]
[PDF]
|
|
|
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114 |
| |
JE Tepper, MJ O'Connell, GR Petroni, D Hollis, E Cooke, AB Benson, 3rd, B Cummings, LL Gunderson, JS Macdonald, and JA Martenson |
| |
JCO May 1 1997: 2030–2039.
[Abstract]
[PDF]
|
|
|
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups |
| |
H Bartelink, F Roelofsen, F Eschwege, P Rougier, JF Bosset, DG Gonzalez, D Peiffert, M van Glabbeke, and M Pierart |
| |
JCO May 1 1997: 2040–2049.
[Abstract]
[PDF]
|
|
|
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? |
| |
PM Harari |
| |
JCO May 1 1997: 2050–2055.
[Abstract]
[PDF]
|
|
|
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? |
| |
R Lenzi, KR Hess, MC Abbruzzese, MN Raber, NG Ordonez, and JL Abbruzzese |
| |
JCO May 1 1997: 2056–2066.
[Abstract]
[PDF]
|
|
|
Survival of differentiated thyroid carcinoma studied in 500 patients |
| |
H Lerch, O Schober, T Kuwert, and HB Saur |
| |
JCO May 1 1997: 2067–2075.
[Abstract]
[PDF]
|
|
|
Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas |
| |
PA Forsyth, E Petrov, H Mahallati, JG Cairncross, P Brasher, ME MacRae, NA Hagen, P Barnes, and RJ Sevick |
| |
JCO May 1 1997: 2076–2081.
[Abstract]
[PDF]
|
|
|
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study |
| |
JL Pujol, JY Douillard, A Riviere, E Quoix, JL Lagrange, P Berthaud, M Bardonnet-Comte, V Polin, V Gautier, B Milleron, F Chomy, P Chomy, D Spaeth, and T Le Chevalier |
| |
JCO May 1 1997: 2082–2089.
[Abstract]
[PDF]
|
|
|
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group |
| |
A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, S Kaplan, P Postmus, G Giaccone, B Schaefer, J Wanders, and J Verweij |
| |
JCO May 1 1997: 2090–2096.
[Abstract]
[PDF]
|
|
|
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study |
| |
RP Perng, YM Chen, J Ming-Liu, CM Tsai, WC Lin, KY Yang, and J Whang-Peng |
| |
JCO May 1 1997: 2097–2102.
[Abstract]
[PDF]
|
|
|
Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m |
| |
WD Quan, Jr, GE Dean, L Spears, CP Spears, S Groshen, JA Merritt, and MS Mitchell |
| |
JCO May 1 1997: 2103–2110.
[Abstract]
[PDF]
|
|
|
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma |
| |
ES Casper, GK Schwartz, A Sugarman, D Leung, and MF Brennan |
| |
JCO May 1 1997: 2111–2117.
[Abstract]
[PDF]
|
|
|
Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy |
| |
G Schwartsmann, E Sprinz, M Kromfield, L Kalakun, E Sander, G Prolla, L Di Leone, L Gerhardt, and DR Mans |
| |
JCO May 1 1997: 2118–2124.
[Abstract]
[PDF]
|
|
|
Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction |
| |
BC Widemann, FM Balis, RF Murphy, JM Sorensen, MJ Montello, M O'Brien, and PC Adamson |
| |
JCO May 1 1997: 2125–2134.
[Abstract]
[PDF]
|
|
|
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone |
| |
MG Kris, KB Pendergrass, RM Navari, TH Grote, AM Nelson, V Thomas, BB Ferguson, DS Allman, BA Pizzo, TW Baker, IJ Fernando, and SB Chernoff |
| |
JCO May 1 1997: 2135–2138.
[Abstract]
[PDF]
|
|
|
Hereditary cancer risk notification and testing: how interested is the general population? |
| |
MA Andrykowski, R Lightner, JL Studts, and RK Munn |
| |
JCO May 1 1997: 2139–2148.
[Abstract]
[PDF]
|
|
|
Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology |
| |
|
| |
JCO May 1 1997: 2149–2156.
[Abstract]
[PDF]
|
|
|
Resource document for curriculum development in cancer genetics education. American Society of Clinical Oncology |
| |
|
| |
JCO May 1 1997: 2157–2169.
[Abstract]
[PDF]
|
|
| Diagnosis in Oncology. Leukemia cutis |
| WC Hahn, D Jones, P Leavitt, J Garber, R Stone, and AT Skarin |
|
JCO May 1 1997: 2170–2171.
[PDF]
|
|
| Survival benefit in melanoma |
| MV Williams, P De Takats, and M Parmar |
|
JCO May 1 1997: 2172a.
[PDF]
|
|
| More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine |
| CF Pollera |
|
JCO May 1 1997: 2172b–2174.
[PDF]
|
|
| Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial |
| T Brodowicz, R Kotz, C Wiltschke, CC Zielinski, and P Ritschl |
|
JCO May 1 1997: 2174–2175.
[PDF]
|
|
| Tumor marker guidelines |
| RB Sklaroff |
|
JCO May 1 1997: 2175–2176.
[PDF]
|
|
| Sinus histiocytosis with massive lymphadenopathy: complete response to low-dose interferon-alpha |
| L Palomera, JM Domingo, T Olave, S Romero, and M Gutierrez |
|
JCO May 1 1997: 2176.
[PDF]
|
|
